Global InformationSemaglutide information
 | |
 Experimentally determined structure of semaglutide while complexed with the GLP-1 receptor. PDB: 7KI0 | |
| Clinical data | |
|---|---|
| Pronunciation | /sɛmˈæɡlʊtaɪd/ sem-AG-luu-tyde or /ˌsɛməˈɡluːtaɪd/ SEM-ə-GLOO-tyde |
| Trade names | Ozempic, Rybelsus, Wegovy, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618008 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Subcutaneous, oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 89% |
| Metabolism | Proteolysis |
| Elimination half-life | 7 days |
| Duration of action | 63.6 h |
| Excretion | Urine and feces |
| Identifiers | |
IUPAC name
| |
| CAS Number |
|
| PubChem CID |
|
| DrugBank |
|
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| ChEBI |
|
| ECHA InfoCard | 100.219.541 |
| Chemical and physical data | |
| Formula | C187H291N45O59 |
| Molar mass | 4113.641 g·mol−1 |
| 3D model (JSmol) |
|
SMILES
| |
InChI
| |
Semaglutide is an antidiabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management.[19][20][21] It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain.[22][23] It can be administered by subcutaneous injection or taken orally.[24][13][14][15] It is sold under the brand names Ozempic[13] and Rybelsus[14] for diabetes, and under the brand name Wegovy for weight loss.[15]
Semaglutide is a glucagon-like peptide-1 receptor agonist.[13][14][15] The most common side effects include nausea, vomiting, diarrhea, abdominal pain, and constipation.[13][16][17][18][25]
It was approved for medical use in the US in 2017.[13][26] In 2021, it was the 90th most commonly prescribed medication in the United States, with more than 8 million prescriptions.[27][28]
- ^ a b Cite error: The named reference
AusPAR: Semaglutidewas invoked but never defined (see the help page). - ^ a b "Rybelsus APMDS". Therapeutic Goods Administration (TGA). 22 February 2022. Retrieved 23 February 2022.
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
- ^ Cite error: The named reference
TGA Ozempicwas invoked but never defined (see the help page). - ^ "Summary for ARTG Entry: 346198 Rybelsus semaglutide 3 mg tablet blister pack". Therapeutic Goods Administration (TGA). Archived from the original on 24 February 2022. Retrieved 23 February 2022.
- ^ "Wegovy (Novo Nordisk Pharmaceuticals Pty Ltd)". Therapeutic Goods Administration (TGA). 7 October 2022. Archived from the original on 14 April 2023. Retrieved 7 April 2023.
- ^ Product Monograph Including Patient Medication Information – Ozempic semaglutide injection (PDF) (Report). Novo-Nordisk Canada. 21 August 2020 [Initial approval 4 January 2018]. Archived (PDF) from the original on 7 June 2021. Retrieved 6 June 2021.
- ^ Product Monograph Including Patient Medication Information – Rybelsus semaglutide tablets (PDF) (Report). Novo-Nordisk Canada. 30 March 2020. Archived (PDF) from the original on 14 December 2021. Retrieved 6 June 2021.
- ^ "Regulatory Decision Summary – Rybelsus". Health Canada. 23 October 2014. Archived from the original on 5 June 2022. Retrieved 4 June 2022.
- ^ "Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. 14 October 2020. Retrieved 17 April 2024.
- ^ "Ozempic 0.25 mg solution for injection in pre-filled pen – Summary of Product Characteristics (SmPC)". (emc). 9 April 2021. Archived from the original on 6 June 2021. Retrieved 6 June 2021.
- ^ "Rybelsus – Summary of Product Characteristics (SmPC)". (emc). 25 November 2020. Archived from the original on 6 June 2021. Retrieved 6 June 2021.
- ^ a b c d e f Cite error: The named reference
Ozempic FDA labelwas invoked but never defined (see the help page). - ^ a b c d Cite error: The named reference
Rybelsus FDA labelwas invoked but never defined (see the help page). - ^ a b c d Cite error: The named reference
Wegovy FDA labelwas invoked but never defined (see the help page). - ^ a b Cite error: The named reference
Ozempic EPARwas invoked but never defined (see the help page). - ^ a b Cite error: The named reference
Rybelsus EPARwas invoked but never defined (see the help page). - ^ a b Cite error: The named reference
Wegovy EPARwas invoked but never defined (see the help page). - ^ Singh G, Krauthamer M, Bjalme-Evans M (January 2022). "Wegovy (semaglutide): a new weight loss drug for chronic weight management". Journal of Investigative Medicine. 70 (1): 5–13. doi:10.1136/jim-2021-001952. PMC 8717485. PMID 34706925.
- ^ Phillips A, Clements JN (February 2022). "Clinical review of subcutaneous semaglutide for obesity". Journal of Clinical Pharmacy and Therapeutics. 47 (2): 184–193. doi:10.1111/jcpt.13574. PMID 34964141. S2CID 245538758.
- ^ Amaro A, Sugimoto D, Wharton S (January 2022). "Efficacy and safety of semaglutide for weight management: evidence from the STEP program". Postgraduate Medicine. 134 (sup1): 5–17. doi:10.1080/00325481.2022.2147326. PMID 36691309. S2CID 256192982.
- ^ Cite error: The named reference
doggrellwas invoked but never defined (see the help page). - ^ Cite error: The named reference
goldenbergwas invoked but never defined (see the help page). - ^ Hughes S, Neumiller JJ (January 2020). "Oral Semaglutide". Clinical Diabetes. 38 (1): 109–111. doi:10.2337/cd19-0079. PMC 6969659. PMID 31975761.
- ^ "Ozempic Drug Trial Snapshot". U.S. Food and Drug Administration (FDA). 5 December 2017. Archived from the original on 31 December 2023. Retrieved 31 December 2023.
This article incorporates text from this source, which is in the public domain.
- ^ Cite error: The named reference
Ozempic FDA approvalwas invoked but never defined (see the help page). - ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
- ^ "Semaglutide - Drug Usage Statistics". ClinCalc. Archived from the original on 8 October 2022. Retrieved 14 January 2024.
